Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (970)	1/11/1999 11:36:00 PM
From: BRAVEHEART	Read Replies (1) \| Respond to of 1477

Frankly Miljenko, I would butcher the scientific understandings but I will ask. My contact is infrequent so be patient. I am more of an all purpose sort. Very analytic. Capable of reading charts & predicting based upon comparative analysis. In fact I am afraid I may buy in just before a technical correction. However, I believe the momentum of this month will carry the day. Normally I wouldn't buy until there was some sort of correction here ( back to say eight ) but the FDA approval is too enticing. I am always well intended in my views. RE: Todays News, I agree that second trials are not the greatest news short term. The additional PII vascular trials do suggest some success and in fact is encouraging long term. I would read into this that the company is going to design better trials with greater chances of success. Hopefully. I would be curious to know if there is any study on the frequency of success of second PII trials. I would presume the success rate is much higher than that of initial PII trials. Just trying to be optimistic as a newly annoited SCIOS shareholder beginning tomorrow. THE TRUTH IS OUT THERE LONE WOLF

To: Miljenko Zuanic who wrote (970)	1/12/1999 11:34:00 AM
From: Rudy Saucillo	Read Replies (1) \| Respond to of 1477

[<<Fiblast® (trafermin) is in Phase II/III clinical trials in Europe for the treatment of stroke and additional Phase II clinical trials in vascular disease are planned.>> So, current data from completed PII trials in vascular diseases are not sufficient for pivotal trial. Chiron does have advantage for now. I am not happy with this.] MZ... I have to admit that I see this news differently than you. I see this as a sign that sufficient progress has been made to continue testing in subsequent trials. I would expect that protocols will be different to test, for example, different modes of delivery (intra-muscular, intra-arterial, intra-venous, etc.). The papers I've seen on the subject (which, by the way, discuss early results in humans for FGF-1 and VEGF165) all describe the need for extensive testing to determine the optimal anatomic site, number, and dose of injections. I think there's still much PhII work to be done before pivotal trials can start, but that definite progress has been made. Now that SCIO has several PhII trials under their belt, I don't see that CHIR has any advantage. Would be nice if SCIO outlined their plans at H&Q. Rudy